MedTrace Logo

Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.

NCT05425550 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2025-09-22

No results posted yet for this study

Summary

Multicenter, prospective, randomised and controlled study to evaluate the medidux™ app during an observation period of 12 weeks (maximum 16 weeks in case of shifts in the initially planned therapy).

Conditions

Interventions

DEVICE

medidux™ app

Use of the regular medidux™ application for 12 (maximum 16) weeks

Sponsors & Collaborators

  • Mobile Health AG

    collaborator INDUSTRY

  • Palleos Healthcare GmbH

    lead INDUSTRY

Principal Investigators

  • Andreas Trojan, Prof. Dr. · Seespital Horgen-Onkologie

  • Peter Fasching, Prof. Dr. · Universitätsklinikum Erlangen; Frauenklinik

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-29
Primary Completion
2025-06-05
Completion
2025-06-05

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05425550 on ClinicalTrials.gov